What is ASND's current stock price?

ASND (Ascendis Pharma A/S) is currently trading at $247.05 with a market cap of $15.26B.

What sector is Ascendis Pharma A/S in?

Ascendis Pharma A/S (ASND) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ASND a good stock to buy?

Analysts have a Buy consensus on ASND with a price target of $287.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ASND Ascendis Pharma A/S

Healthcare

$247.05-0.19%ClosedMarket Cap: $15.26B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

26.80

P/S

15.11

EV/EBITDA

-1935.12

DCF Value

$-4,957.90

FCF Yield

0.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

88.2%

Operating Margin

-0.8%

Net Margin

58.4%

ROE

-5641.9%

ROA

25.3%

ROIC

1.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$250.7M	$639.7M	$—
Q4 null	$245.2M	$-33.2M	$—
FY null	$691.7M	$-219.0M	$—
Q3 null	$213.6M	$-61.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$287.50

Target (Median)

$267.50

Target Range

$250.00 - $345.00

4 Strong Buy13 Buy0 Hold0 Sell0 Strong Sell

Evercore ISI GroupOutperform

2026-05-15

BarclaysOverweight

2026-05-11

Wells FargoOverweight

2026-05-08

B of A SecuritiesBuy

2026-04-16

WedbushOutperform

2026-04-09

Trading Activity

Insider Trades

View All

JENSEN FLEMMING STEENofficer: See Remarks

SellTue May 12

BIENAIME JEAN JACQUESdirector

SellWed Apr 01

BIENAIME JEAN JACQUESdirector

SellWed Apr 01

SMITH SCOTT THOMASofficer: EVP & Chief Financial Officer

SellWed Mar 18

SMITH SCOTT THOMASofficer: EVP & Chief Financial Officer

SellWed Mar 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.41

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Peers